Home>News Center>World
             
     

    Potential HIV/AIDS vaccine gets more tests
    (Agencies)
    Updated: 2005-01-25 20:51

    NEWARK, N.J. - A potential HIV/AIDS vaccine developed by Merck & Co. that uses synthetic genes to prepare cells to fight the deadly virus is moving into the second stage of testing.

    An approved vaccine would be about a decade away if the trial and a third study are successful, said officials with the international coalition that is collaborating on the work.

    "It is the most promising candidate that we've seen so far," said Sarah B. Alexander, associate director of the coalition, known as the HIV Vaccine Trials Network, or HVTN. She cautioned, however, "something better could come along tomorrow."

    Volunteers began enrolling last month for the Phase II study, which will eventually give the potential vaccine's three doses to 1,500 people in North and South America, the Caribbean and Australia, the network and Whitehouse Station-based drug maker announced Monday.

    The study is using male and female volunteers aged 18 to 45 of diverse racial groups who are at high risk for contracting HIV. Participants will receive counseling about how to reduce their risk of HIV infection, Alexander said.

    About a dozen companies and organizations worldwide are attempting to develop an AIDS vaccine. Of the 10 associated with HVTN, the Merck candidate is the first to reach Phase II testing, Alexander said.

    Of the two that reached Phase III, the final stage before certification is sought, one was deemed unsuccessful in 2000, and another, led by the U.S. Department of Defense, is enrolling volunteers, she said.

    The Merck candidate — the MRKAd5 HIV-1 gag/pol/nef, or trivalent, vaccine — is designed to persuade the defenders of each cell, called "killer T cells," to attack HIV when the virus enters the cell. Other vaccines generate an antibody response.

    The potential vaccine uses the virus of a common cold, modified so it cannot reproduce or cause people to catch a cold, to transport three synthetically produced HIV genes to the cells.

    "We give the body enough of the virus so it can recognize it and create an immune response," but not enough to infect a person, Alexander said.

    The Phase I study of the possible vaccine, involving about 1,000 people, "generated strong and durable cellular immune responses against HIV," Merck spokeswoman Janet Skidmore said.

    Seattle-based HVTN is funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, an agency of the US Department of Health and Human Services, and comprises more than 25 research institutions worldwide.

    Merck shares fell 51 cents, or 1.7 percent, to close at $29.85 in Monday trading on the New York Stock Exchange. The stock, which has fallen sharply since Merck withdrew its Vioxx drug from the market amid safety concerns, has traded in a 52-week range of $25.60 to $49.33.



     
      Today's Top News     Top World News
     

    China's GDP grows 9.5% in 2004, higher than forecasts

     

       
     

    Revision of law to upgrade mine safety

     

       
     

    FM says released men to fly back soon

     

       
     

    Myanmar nabs drug lord, sends him back

     

       
     

    China seeks to curb corruption in big SOEs

     

       
     

    Bank officials flee after US$120m go missing

     

       
      Potential HIV/AIDS vaccine gets more tests
       
      Stampede at Hindu procession kills 150
       
      11 policemen killed in Baghdad clashes
       
      UN: World needs the will to stop genocide
       
      Iraq forces arrest top al-Qaida lieutenant
       
      Torture still routine in Iraqi jails: report
       
     
      Go to Another Section  
     
     
      Story Tools  
       
      Related Stories  
       
    Shanxi to test blood sellers for HIV
       
    Checking mother-to-child HIV transmission
       
    India to step up AIDS fight, launch media campaign
       
    Boosting rights of HIV victims
       
    Thai-Chinese anti-HIV drug 89% effective
       
    HIV pregnant women to be treated free
       
    HIV infection rates unchanged in US
      News Talk  
      Are the Republicans exploiting the memory of 9/11?  
    Advertisement
             
    在线观看中文字幕| 无码中文人妻视频2019| 久久AV无码精品人妻糸列 | 久久青青草原亚洲av无码app| 天堂新版8中文在线8| 四虎成人精品国产永久免费无码| 伊人久久精品无码二区麻豆| 天堂网在线最新版www中文网| 无码日韩人妻AV一区二区三区| 亚洲AV无码精品无码麻豆| 久久中文精品无码中文字幕| AV色欲无码人妻中文字幕| 成人午夜福利免费专区无码| 无码中文字幕乱在线观看| 日韩AV无码一区二区三区不卡毛片 | 无码日韩人妻AV一区免费l| 无码国内精品人妻少妇蜜桃视频| 中文字幕精品久久久久人妻| 日韩精品中文字幕无码一区| 亚洲av无码专区在线观看素人| 久久精品中文字幕无码绿巨人| 中文字幕精品无码一区二区三区| 最近中文字幕2019视频1| 在线免费中文字幕| 中文字幕亚洲综合精品一区| 三级理论中文字幕在线播放| 中文字幕一区二区人妻| 久久中文字幕人妻熟av女| 曰韩无码AV片免费播放不卡| 亚洲国产精品无码久久青草| 蜜臀AV无码国产精品色午夜麻豆 | 精品无码国产污污污免费网站国产| 色欲A∨无码蜜臀AV免费播 | 免费无码一区二区三区蜜桃| 无码人妻少妇久久中文字幕| 中文字幕日韩三级片| 亚洲va中文字幕无码| 日日摸夜夜爽无码毛片精选| 无码人妻一区二区三区一| 成人午夜精品无码区久久| 无码人妻久久久一区二区三区|